Piramal Enterprises’ healthcare vertical enters into strategic alliance with Fujifilm

30 Oct 2012 Evaluate

Piramal Enterprises’ healthcare vertical has entered into a strategic alliance with Fujifilm Diosynth Biotechnologies, for co-operation in biopharmaceuticals for developing new therapies, including that of cancer. As per the alliance, the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

The alliance besides allowing customers to benefit from the experience and assets of both organizations, would simplify the supply chain and vendor management relationships, leading to shorter time to clinic.

Piramal is a world leader in antibody drug conjugation, whilst Fujifilm Diosynth Biotechnologies is among the leading biologics contract development and manufacturing organisations with experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among others. The combined experience of bother the organizations covers work on more than 150 biopharma and over 300 batches of ADCs spanning over more than 30 different NCEs, including the world’s only FDA-approved ADC.

Piramal Enterprises Share Price

827.90 1.10 (0.13%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Bajaj Finance 6740.00
Shriram Finance 2366.85
Aditya Birla Capital 223.45
SBI Cards AndPayment 714.50
Chola Invest & Fin. 1280.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.